Clinical problems with generic antiepileptic drugs. Comparison of sustained-release formulations of carbamazepine

Clinical Drug Investigation

Volumn 18, Issue 1, 1999, Pages 17-26

  Mayer, Thomas ^a   May, T W ^a   Altenmuller D M ^a   Sandmann, M ^a   Wolf, P ^a  

^a EPILEPSY CENTER BETHEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; FOKALEPSIN 300 RETARD; GENERIC DRUG; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPLOPIA; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG SOLUBILITY; EPILEPSY; FEMALE; HUMAN; MALE; NAUSEA; NYSTAGMUS; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; VERTIGO;

EID: 0032813755     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918010-00003     Document Type: Article

References (32)

1. 1. Blume H, Mutschler E. Bioäquivalenz: qualitätsbewertung inhaltsgleicher Fertigarzneimittel. Im: Auftrag der Bundesvercinigung Dt. Apothekerverband ed. Frankfurt: Govi-Verlag, 1996
2. 2. CPMP (Committee for Proprietary Medicinal Products) Working Party on the Efficacy of Medicinal Products. Notes for guidance: investigation of bioavailability and bioequivalence. The rules governing medicinal products in the European Community 1991; 3: 149-67
3. 3. Balla J. Dilantin overdosage [letter]. Med J Aust 1968; 2: 480-1
4. 4. Eadie MJ, Sutherland JM, Tyrer JH. Dilantin overdosage [letter]. Med J Aust 1968; 2: 515
5. 5. Tyrer JH, Eadie, MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970; 4: 271-3
6. 6. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology 1990; 40: 1641-3
7. 7. Jürgens U. HPLC analysis of antiepileptic drugs in blood samples: microbore separation of fourteen compounds. J Liquid Chromatogr 1987; 10 (2,3): 507-32
8. 8. Holmes GL. Carbamazepine toxicity. In: Levy RH, Mattson RH, editors. Antiepileptic drugs, 4th edition. New York: Raven Press, 1995: 667-72
9. 9. Busch RL. Generic carbamazepine and erythema multiforme: generic-drug nonequivalence [letter]. N Engl J Med 1989; 316: 692-3
10. 10. Gashko MA. Generic substitution for antiepileptic drugs [letter]. Neurology 1991; 44: 1165
11. 11. Glende M, Hüller H, Mai I, et al. Comparative bioavailability of two carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1983; 21 (12): 631-3
12. 12 Hartley R, Aleksandowicz J, Ng PC, et al. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability? Br J Clin Pract 1990; 44 (7): 270-3
13. 13. Hartley R, Aleksandowicz J, Bowmer CJ, et al. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. J Pharm Pharmacol 1991; 43: 117-9
14. 14. Hirji MR, Measuria H, Kuhn S, et al. A comparative study of the bioavailability of five different phenytoin preparations. J Pharm Pharmacol 1985; 37: 570-2
15. 15. Jain KK. Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. J R Soc Med 1993; 86: 133-6
16. 16. Jumao-as A, Bella I, Craig B, et al. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 1989; 30: 67-70
17. 17 Kauko K, Tammistro P. Comparison of two generically equivalent carbamazepine preparations. Ann Clin Res 1974; 6 Suppl. II: 21-5
18. 18. Meyer MC, Straughn AB, Jarvi EJ, et al. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992; 9 (12): 1612-6
19. 19. Neuvonen PJ. Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol 1985; 23 (4): 226-32
20. 20. Nuwer MR, Browne TR, Dodson WE, et al. Generic substitutions for antiepileptic drugs. Neurology 1990; 40: 1647-51
21. 21. Oles KS, Penry JK, Smith LD, et al. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42: 1147-53
22. 22. Sachdeo, RC, Belendiuk G. Generic versus branded carbamazepine [letter]. Lancet 1987; 1: 1432
23. 23. Silpakit O, Amornpichetkoon M, Kaojarem S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997; 31 548-52
24. 24. Trimble MR. Generic prescribing. Hum Psychopharmacol 1987; 2: 1-2
25. 25. Welty TE, Pickering PR, Hale BC, et al. Loss of seizure control associated with generic substitution of carbamazepine. Ann Pharmacother 1992; 26: 775-7
26. 26. Wolf P, May Th, Tiska G, et al. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimforschung Drug Res 1992; 42 (3): 3-15
27. 27. Wolf P. Die Generika kommen. Epilepsie-Blätter 1993; 6; 40-2
28. 28. Wolf P. Die Generika sind da. Epilepsie-Blätter 1996; 9: 16-7
29. 29. Crawford P, Hall WH, Collings J, et al. Generic prescribing for epilepsy. Is it safe? Seizure 1996; 5 (1): 1-5
30. 30. Beach R, Reading R. Correspondence: generic prescribing for epilepsy. Is it safe? [letter]. Seizure 1997; 6: 327
31. 31. Richens A. Impact of generic substitution of anticonvulsants in the treatment of epilepsy. CNS Drugs 1997; 8: 124-33
32. 32. Bialer M, Yacobi A, Moros D, et al. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 1998; 39 (5): 513-9